Based on these findings, the anti-TIM-3 mAb MBG453 is currently evaluated in a phase I clinical trial for r/r AML and high-risk MDS, combined with Decitabine, a nucleic acid synthesis inhibitor (NCT03066648). The gene discussed is HAVCR2; the disease is myelodysplastic syndrome.